Home » Stocks » GALT

Galectin Therapeutics Inc. (GALT)

Stock Price: $2.24 USD -0.05 (-2.18%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $2.30 +0.06 (2.68%) Feb 26, 6:30 PM
Market Cap 130.71M
Revenue (ttm) n/a
Net Income (ttm) -20.89M
Shares Out 57.05M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $2.24
Previous Close $2.29
Change ($) -0.05
Change (%) -2.18%
Day's Open 2.27
Day's Range 2.15 - 2.29
Day's Volume 229,225
52-Week Range 1.50 - 3.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 months ago

NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boud...

GlobeNewsWire - 2 months ago

Chairman Dick Uihlein, CEO and President Joel Lewis, and Chief Medical Officer Pol Boudes Provide Corporate Highlights on Company's Three Active Clinical Trials Chairman Dick Uihlein, CEO and ...

GlobeNewsWire - 3 months ago

Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated

GlobeNewsWire - 4 months ago

Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel Lewis Presentation to discuss the details of the newly launche...

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.

GlobeNewsWire - 5 months ago

Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel Lewis Presentation to discuss the details of the newly launche...

GlobeNewsWire - 5 months ago

NORCROSS, Ga., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that mana...

GlobeNewsWire - 5 months ago

Dr. Harold Shlevin retires as CEO, transitions to role of scientific and business consultant and will remain on the Board

GlobeNewsWire - 6 months ago

NASH-RX Trial Continues to Enroll New Patients NASH-RX Trial Continues to Enroll New Patients

Seeking Alpha - 7 months ago

Intercept's Pain Is Galectin's Gain: Clinical Outcomes In NASH Are Crucial

GlobeNewsWire - 7 months ago

Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy

GlobeNewsWire - 7 months ago

Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in Galectin Therapeutics.

GlobeNewsWire - 9 months ago

NASH-RX Clinical Trial Protocol Filed with FDA; First Patient Currently Expected to be Enrolled in Second Quarter 2020

GlobeNewsWire - 9 months ago

The first patient currently expected to be enrolled in the second quarter of 2020 The first patient currently expected to be enrolled in the second quarter of 2020

Seeking Alpha - 9 months ago

Finding The Kink In COVID-19's Armor - Preventing ARDS

Other stocks mentioned: AMPE, CYDY, GILD, RHHBY
GlobeNewsWire - 10 months ago

NORCROSS, Ga., April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on ...

Seeking Alpha - 1 year ago

Galectin Therapeutics: An Even Better Buy As It Hits 52-Week Lows

GlobeNewsWire - 1 year ago

Interim analysis after 12-18 months of treatment to reaffirm phase 2 results, select optimal dosage and sizing and seamlessly roll into Phase 3 stage of NASH-RX Study

Zacks Investment Research - 1 year ago

Small Drug Stock Outlook: Innovation Holds the Key to Growth

Other stocks mentioned: LCI, VRCA, ZTS
Seeking Alpha - 1 year ago

I provide a basic overview of Galectin Therapeutics, and where it, and galectin-3 research, stands today.

Other stocks mentioned: MRK
Seeking Alpha - 1 year ago

Since Galectin announced funding plans for the Phase 3 trial via a rights offering, most investors have waited "patiently" for updates on the clinical and financial plans.

Seeking Alpha - 1 year ago

Recent third-party research bodes well for GALT's GR-MD-02.

About GALT

Galectin Therapeutics, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate is GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical d... [Read more...]

Industry
Biotechnology
Founded
2000
CEO
Harold Shlevin
Employees
4
Stock Exchange
NASDAQ
Ticker Symbol
GALT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for GALT stock is "Buy" and the 12-month stock price forecast is 12.00.

Price Target
$12.00
Analyst Consensus: Buy